[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fe3_hf8coBqOy_11yK2J2SzhxkOA2uER706lpjJS9WS8":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":8,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":33,"phaseBuckets":39,"rows":46},"Bayside Health",[4],111,false,1,10,34750,67,[13,16,18,21,24,26,28,31],{"name":14,"count":15},"HIV Infections",6,{"name":17,"count":15},"Cystic Fibrosis",{"name":19,"count":20},"Type 2 Diabetes",5,{"name":22,"count":23},"Obesity",4,{"name":25,"count":23},"Schizophrenia",{"name":27,"count":23},"Cardiovascular Disease",{"name":29,"count":30},"Depression",3,{"name":32,"count":30},"Hepatitis C",[34],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT05470816","Tranexamic Acid to Reduce Delirium After Gastrointestinal Surgery: the TRIGS-D Trial","2026-08-13","Tranexamic Acid 100Mg\u002Fml Inj Vial 10ml",[40,41,42,43,44,45],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[47,73,113,151,173,199,225,251,276,300,327,352,378,404,429,460,478,503,528,555,578,603,628,653,678,702,728,757,781,799,826,844,862,880,905,929,951,975,997,1021,1047,1070,1093,1118,1136,1159,1182,1204,1230],{"intervention":38,"totalTrials":8,"cells":48},{"EARLY_PHASE1":49,"PHASE1":52,"PHASE2":54,"PHASE3":56,"PHASE4":69,"NA":71},{"trials":50,"activeCount":51},[],0,{"trials":53,"activeCount":51},[],{"trials":55,"activeCount":51},[],{"trials":57,"activeCount":8,"soonestReadout":37},[58],{"nctId":35,"briefTitle":36,"status":59,"phases":60,"primaryCompletion":37,"completion":61,"start":62,"enrollment":63,"conditions":64,"interventions":68},"ACTIVE_NOT_RECRUITING",[43],"2026-08-31","2022-11-01",826,[65,66,67],"Surgical Site Infection","Dementia","Cognition",[38],{"trials":70,"activeCount":51},[],{"trials":72,"activeCount":51},[],{"intervention":74,"totalTrials":75,"cells":76},"Nitrous Oxide",2,{"EARLY_PHASE1":77,"PHASE1":79,"PHASE2":81,"PHASE3":95,"PHASE4":97,"NA":111},{"trials":78,"activeCount":51},[],{"trials":80,"activeCount":51},[],{"trials":82,"activeCount":51},[83],{"nctId":84,"briefTitle":85,"status":86,"phases":87,"primaryCompletion":88,"completion":89,"start":90,"enrollment":91,"conditions":92,"interventions":94},"NCT03869736","Nitrous Oxide for the Treatment of Major Depressive Disorder","COMPLETED",[42],"2023-06-10","2023-12-10","2019-01-22",81,[29,93],"Major Depressive Disorder",[74],{"trials":96,"activeCount":51},[],{"trials":98,"activeCount":51},[99],{"nctId":100,"briefTitle":101,"status":86,"phases":102,"primaryCompletion":103,"completion":103,"start":104,"enrollment":105,"conditions":106,"interventions":110},"NCT00164047","ENIGMA - Evaluation of Nitrous Oxide In the Gas Mixture for Anaesthesia: a Randomised Controlled Trial",[44],"2004-12","2003-04",2070,[107,108,109],"Quality of Recovery From Anaesthesia","Effects of Nitrous Oxide Following Anaesthesia","Induced Endothelial Dysfunction",[74],{"trials":112,"activeCount":51},[],{"intervention":114,"totalTrials":75,"cells":115},"ivabradine",{"EARLY_PHASE1":116,"PHASE1":118,"PHASE2":120,"PHASE3":122,"PHASE4":124,"NA":149},{"trials":117,"activeCount":51},[],{"trials":119,"activeCount":51},[],{"trials":121,"activeCount":51},[],{"trials":123,"activeCount":51},[],{"trials":125,"activeCount":51},[126,138],{"nctId":127,"briefTitle":128,"status":129,"phases":130,"primaryCompletion":131,"completion":131,"start":132,"enrollment":133,"conditions":134,"interventions":136},"NCT01029223","The Influence of Heart Rate Reduction Upon Central Arterial Pressure in Younger and Older Healthy Individuals","WITHDRAWN",[44],"2011-12","2008-10",42,[135],"Blood Pressure",[114,137],"metoprolol",{"nctId":139,"briefTitle":140,"status":141,"phases":142,"primaryCompletion":143,"completion":143,"start":132,"enrollment":75,"conditions":144,"interventions":146},"NCT00825123","Effects of Heart Rate Reduction on Central Arterial Pressure in Healthy Individuals","TERMINATED",[44],"2011-11-08",[145],"Central Arterial Pressure",[147,148],"Ivabradine","Metoprolol",{"trials":150,"activeCount":51},[],{"intervention":137,"totalTrials":75,"cells":152},{"EARLY_PHASE1":153,"PHASE1":155,"PHASE2":157,"PHASE3":159,"PHASE4":161,"NA":171},{"trials":154,"activeCount":51},[],{"trials":156,"activeCount":51},[],{"trials":158,"activeCount":51},[],{"trials":160,"activeCount":51},[],{"trials":162,"activeCount":51},[163,167],{"nctId":127,"briefTitle":128,"status":129,"phases":164,"primaryCompletion":131,"completion":131,"start":132,"enrollment":133,"conditions":165,"interventions":166},[44],[135],[114,137],{"nctId":139,"briefTitle":140,"status":141,"phases":168,"primaryCompletion":143,"completion":143,"start":132,"enrollment":75,"conditions":169,"interventions":170},[44],[145],[147,148],{"trials":172,"activeCount":51},[],{"intervention":174,"totalTrials":8,"cells":175},"Rosuvastatin",{"EARLY_PHASE1":176,"PHASE1":178,"PHASE2":180,"PHASE3":182,"PHASE4":184,"NA":197},{"trials":177,"activeCount":51},[],{"trials":179,"activeCount":51},[],{"trials":181,"activeCount":51},[],{"trials":183,"activeCount":51},[],{"trials":185,"activeCount":51},[186],{"nctId":187,"briefTitle":188,"status":86,"phases":189,"primaryCompletion":190,"completion":191,"start":192,"enrollment":193,"conditions":194,"interventions":196},"NCT01813357","Does Rosuvastatin Delay Progression of Atherosclerosis in HIV",[44],"2018-05-17","2018-11-01","2013-07-02",84,[195,27],"HIV",[174],{"trials":198,"activeCount":51},[],{"intervention":200,"totalTrials":8,"cells":201},"(agent for immunotherapy) Staloral",{"EARLY_PHASE1":202,"PHASE1":204,"PHASE2":206,"PHASE3":208,"PHASE4":210,"NA":223},{"trials":203,"activeCount":51},[],{"trials":205,"activeCount":51},[],{"trials":207,"activeCount":51},[],{"trials":209,"activeCount":51},[],{"trials":211,"activeCount":51},[212],{"nctId":213,"briefTitle":214,"status":86,"phases":215,"primaryCompletion":216,"completion":216,"start":217,"enrollment":218,"conditions":219,"interventions":222},"NCT00250263","A Trial of Immunological Outcomes of Sublingual Immunotherapy for House Dust Mite (D. Pteronyssinus) Allergy",[44],"2008-12","2005-11",30,[220,221],"Allergic Rhinitis","Asthma",[200],{"trials":224,"activeCount":51},[],{"intervention":226,"totalTrials":8,"cells":227},"Quetiapine XR",{"EARLY_PHASE1":228,"PHASE1":230,"PHASE2":232,"PHASE3":234,"PHASE4":236,"NA":249},{"trials":229,"activeCount":51},[],{"trials":231,"activeCount":51},[],{"trials":233,"activeCount":51},[],{"trials":235,"activeCount":51},[],{"trials":237,"activeCount":51},[238],{"nctId":239,"briefTitle":240,"status":241,"phases":242,"primaryCompletion":243,"completion":243,"start":244,"enrollment":245,"conditions":246,"interventions":248},"NCT00986167","Quetiapine Extended Release (XR) for the Management of Psychotic Aggression or Agitation in Adult Acute Psychiatry","UNKNOWN",[44],"2010-10","2009-10",72,[25,247],"Psychosis",[226],{"trials":250,"activeCount":51},[],{"intervention":252,"totalTrials":8,"cells":253},"Abacavir",{"EARLY_PHASE1":254,"PHASE1":256,"PHASE2":258,"PHASE3":260,"PHASE4":262,"NA":274},{"trials":255,"activeCount":51},[],{"trials":257,"activeCount":51},[],{"trials":259,"activeCount":51},[],{"trials":261,"activeCount":51},[],{"trials":263,"activeCount":51},[264],{"nctId":265,"briefTitle":266,"status":86,"phases":267,"primaryCompletion":268,"completion":269,"start":270,"enrollment":271,"conditions":272,"interventions":273},"NCT01886638","Determining the Effect of Abacavir on Platelet Activation",[44],"2014-06","2014-10","2013-08",23,[195,27],[252],{"trials":275,"activeCount":51},[],{"intervention":277,"totalTrials":8,"cells":278},"Control",{"EARLY_PHASE1":279,"PHASE1":281,"PHASE2":283,"PHASE3":285,"PHASE4":287,"NA":298},{"trials":280,"activeCount":51},[],{"trials":282,"activeCount":51},[],{"trials":284,"activeCount":51},[],{"trials":286,"activeCount":51},[],{"trials":288,"activeCount":51},[289],{"nctId":290,"briefTitle":291,"status":86,"phases":292,"primaryCompletion":293,"start":294,"enrollment":295,"conditions":296,"interventions":297},"NCT02014623","Immunological Mechanisms of Oralair® in Patients With Seasonal Allergic Rhinitis",[44],"2019-11-15","2014-02",51,[220],[277],{"trials":299,"activeCount":51},[],{"intervention":301,"totalTrials":8,"cells":302},"zoledronic acid vs pamidronate",{"EARLY_PHASE1":303,"PHASE1":305,"PHASE2":307,"PHASE3":309,"PHASE4":311,"NA":325},{"trials":304,"activeCount":51},[],{"trials":306,"activeCount":51},[],{"trials":308,"activeCount":51},[],{"trials":310,"activeCount":51},[],{"trials":312,"activeCount":51},[313],{"nctId":314,"briefTitle":315,"status":86,"phases":316,"primaryCompletion":317,"completion":317,"start":318,"enrollment":319,"conditions":320,"interventions":324},"NCT00164008","Comparison of Pamidronate With Zoledronic Acid for Transplant Related Bone Loss Prevention",[44],"2005-12","2002-10",56,[321,322,323],"Osteopenia","Complications of Heart-lung Transplant","Other Complications of Lung Transplant",[301],{"trials":326,"activeCount":51},[],{"intervention":328,"totalTrials":8,"cells":329},"Dexamethasone",{"EARLY_PHASE1":330,"PHASE1":332,"PHASE2":334,"PHASE3":336,"PHASE4":338,"NA":350},{"trials":331,"activeCount":51},[],{"trials":333,"activeCount":51},[],{"trials":335,"activeCount":51},[],{"trials":337,"activeCount":51},[],{"trials":339,"activeCount":51},[340],{"nctId":341,"briefTitle":342,"status":241,"phases":343,"primaryCompletion":344,"completion":344,"start":345,"enrollment":346,"conditions":347,"interventions":349},"NCT03002259","Dexamethasone for Cardiac Surgery-II Trial",[44],"2023-01-31","2018-09-01",1956,[348],"Inflammatory Response",[328],{"trials":351,"activeCount":51},[],{"intervention":353,"totalTrials":8,"cells":354},"Ferric carboxymaltose",{"EARLY_PHASE1":355,"PHASE1":357,"PHASE2":359,"PHASE3":361,"PHASE4":363,"NA":376},{"trials":356,"activeCount":51},[],{"trials":358,"activeCount":51},[],{"trials":360,"activeCount":51},[],{"trials":362,"activeCount":51},[],{"trials":364,"activeCount":51},[365],{"nctId":366,"briefTitle":367,"status":86,"phases":368,"primaryCompletion":369,"completion":370,"start":371,"enrollment":372,"conditions":373,"interventions":375},"NCT02632760","Intravenous Iron for Treatment of Anaemia Before Cardiac Surgery",[44],"2024-04-16","2024-11-27","2016-07-15",955,[374],"Anaemia",[353],{"trials":377,"activeCount":51},[],{"intervention":379,"totalTrials":8,"cells":380},"Eplerenone",{"EARLY_PHASE1":381,"PHASE1":383,"PHASE2":385,"PHASE3":387,"PHASE4":389,"NA":402},{"trials":382,"activeCount":51},[],{"trials":384,"activeCount":51},[],{"trials":386,"activeCount":51},[],{"trials":388,"activeCount":51},[],{"trials":390,"activeCount":51},[391],{"nctId":392,"briefTitle":393,"status":241,"phases":394,"primaryCompletion":395,"completion":396,"start":397,"enrollment":398,"conditions":399,"interventions":401},"NCT02345590","Eplerenone in the Management of Abdominal Aortic Aneurysms",[44],"2018-12","2019-12","2015-05",172,[400],"Aortic Aneurysm, Abdominal",[379],{"trials":403,"activeCount":51},[],{"intervention":405,"totalTrials":8,"cells":406},"ketamine",{"EARLY_PHASE1":407,"PHASE1":409,"PHASE2":411,"PHASE3":413,"PHASE4":415,"NA":427},{"trials":408,"activeCount":51},[],{"trials":410,"activeCount":51},[],{"trials":412,"activeCount":51},[],{"trials":414,"activeCount":51},[],{"trials":416,"activeCount":51},[417],{"nctId":418,"briefTitle":419,"status":86,"phases":420,"completion":421,"start":422,"enrollment":423,"conditions":424,"interventions":426},"NCT00163969","The Use of Ketamine as Rescue Analgesia in the Recovery Room Following Opioid Administration. A Double-blind Randomised Trial in Postoperative Patients",[44],"2004-09","2002-04",40,[425],"Post Operative Pain",[405],{"trials":428,"activeCount":51},[],{"intervention":430,"totalTrials":8,"cells":431},"Tranexamic Acid",{"EARLY_PHASE1":432,"PHASE1":434,"PHASE2":436,"PHASE3":438,"PHASE4":440,"NA":458},{"trials":433,"activeCount":51},[],{"trials":435,"activeCount":51},[],{"trials":437,"activeCount":51},[],{"trials":439,"activeCount":51},[],{"trials":441,"activeCount":51},[442],{"nctId":443,"briefTitle":444,"status":86,"phases":445,"primaryCompletion":446,"completion":447,"start":448,"enrollment":449,"conditions":450,"interventions":456},"NCT04192435","Tranexamic Acid to Reduce Infection After Gastrointestinal Surgery",[44],"2025-09-13","2025-10-20","2022-05-18",3300,[451,452,453,454,455],"Infection Wound","Gastrointestinal Complication","Anesthesia","Bleeding","Healthcare Associated Infection",[430,457],"Placebos",{"trials":459,"activeCount":51},[],{"intervention":457,"totalTrials":8,"cells":461},{"EARLY_PHASE1":462,"PHASE1":464,"PHASE2":466,"PHASE3":468,"PHASE4":470,"NA":476},{"trials":463,"activeCount":51},[],{"trials":465,"activeCount":51},[],{"trials":467,"activeCount":51},[],{"trials":469,"activeCount":51},[],{"trials":471,"activeCount":51},[472],{"nctId":443,"briefTitle":444,"status":86,"phases":473,"primaryCompletion":446,"completion":447,"start":448,"enrollment":449,"conditions":474,"interventions":475},[44],[451,452,453,454,455],[430,457],{"trials":477,"activeCount":51},[],{"intervention":479,"totalTrials":8,"cells":480},"Coversyl",{"EARLY_PHASE1":481,"PHASE1":483,"PHASE2":485,"PHASE3":487,"PHASE4":499,"NA":501},{"trials":482,"activeCount":51},[],{"trials":484,"activeCount":51},[],{"trials":486,"activeCount":51},[],{"trials":488,"activeCount":51},[489],{"nctId":490,"briefTitle":491,"status":86,"phases":492,"completion":493,"start":494,"enrollment":495,"conditions":496,"interventions":498},"NCT00485368","Angiotensin Converting Enzyme Inhibitors in Marfan Syndrome",[43],"2006-09","2004-01",17,[497],"Marfan Syndrome",[479],{"trials":500,"activeCount":51},[],{"trials":502,"activeCount":51},[],{"intervention":504,"totalTrials":8,"cells":505},"Ondansetron",{"EARLY_PHASE1":506,"PHASE1":508,"PHASE2":510,"PHASE3":512,"PHASE4":524,"NA":526},{"trials":507,"activeCount":51},[],{"trials":509,"activeCount":51},[],{"trials":511,"activeCount":51},[],{"trials":513,"activeCount":51},[514],{"nctId":515,"briefTitle":516,"status":86,"phases":517,"primaryCompletion":518,"completion":518,"start":519,"enrollment":520,"conditions":521,"interventions":523},"NCT01121042","Double Blind, Placebo-Controlled, Randomised Investigation of Ondansetron in Schizophrenia",[43],"2018-08","2010-07",85,[522,25],"Schizoaffective and Schizophreniform Disorders",[504],{"trials":525,"activeCount":51},[],{"trials":527,"activeCount":51},[],{"intervention":529,"totalTrials":8,"cells":530},"Elbasvir \u002F Grazoprevir Oral",{"EARLY_PHASE1":531,"PHASE1":533,"PHASE2":535,"PHASE3":537,"PHASE4":551,"NA":553},{"trials":532,"activeCount":51},[],{"trials":534,"activeCount":51},[],{"trials":536,"activeCount":51},[],{"trials":538,"activeCount":51},[539],{"nctId":540,"briefTitle":541,"status":129,"phases":542,"primaryCompletion":543,"completion":544,"start":545,"enrollment":51,"conditions":546,"interventions":550},"NCT04546802","HepATocellular Cancer Hcv Therapy Study",[43],"2021-06","2023-06","2019-09",[547,548,549,32],"Hepatocellular Carcinoma","Hepatoma","Liver Cell Carcinoma",[529],{"trials":552,"activeCount":51},[],{"trials":554,"activeCount":51},[],{"intervention":556,"totalTrials":8,"cells":557},"Normal saline IV, salt",{"EARLY_PHASE1":558,"PHASE1":560,"PHASE2":562,"PHASE3":564,"PHASE4":574,"NA":576},{"trials":559,"activeCount":51},[],{"trials":561,"activeCount":51},[],{"trials":563,"activeCount":51},[],{"trials":565,"activeCount":51},[566],{"nctId":567,"briefTitle":568,"status":241,"phases":569,"completion":570,"start":571,"enrollment":423,"conditions":572,"interventions":573},"NCT00163852","Treatment of Metabolic Alkalosis in Acute Exacerbations of Cystic Fibrosis",[42,43],"2006-02","2004-02",[17],[556],{"trials":575,"activeCount":51},[],{"trials":577,"activeCount":51},[],{"intervention":579,"totalTrials":8,"cells":580},"N-acetylcysteine",{"EARLY_PHASE1":581,"PHASE1":583,"PHASE2":585,"PHASE3":587,"PHASE4":599,"NA":601},{"trials":582,"activeCount":51},[],{"trials":584,"activeCount":51},[],{"trials":586,"activeCount":51},[],{"trials":588,"activeCount":51},[589],{"nctId":590,"briefTitle":591,"status":241,"phases":592,"completion":593,"start":594,"enrollment":9,"conditions":595,"interventions":598},"NCT00532688","N-Acetylcysteine in Heart Failure With Coexistent Chronic Renal Failure",[42,43],"2008-02","2007-09",[596,597],"Heart Failure, Congestive","Kidney Failure, Chronic",[579],{"trials":600,"activeCount":51},[],{"trials":602,"activeCount":51},[],{"intervention":604,"totalTrials":8,"cells":605},"Estradiol",{"EARLY_PHASE1":606,"PHASE1":608,"PHASE2":610,"PHASE3":622,"PHASE4":624,"NA":626},{"trials":607,"activeCount":51},[],{"trials":609,"activeCount":51},[],{"trials":611,"activeCount":51},[612],{"nctId":613,"briefTitle":614,"status":86,"phases":615,"primaryCompletion":103,"completion":103,"start":616,"enrollment":617,"conditions":618,"interventions":621},"NCT00206570","Clinical Estradiol Trial in Women With Schizophrenia",[42],"2001-01",100,[25,619,620],"Schizoaffective Disorder","Schizophreniform Disorder",[604],{"trials":623,"activeCount":51},[],{"trials":625,"activeCount":51},[],{"trials":627,"activeCount":51},[],{"intervention":629,"totalTrials":8,"cells":630},"gemcitabine, vinorelbine",{"EARLY_PHASE1":631,"PHASE1":633,"PHASE2":635,"PHASE3":647,"PHASE4":649,"NA":651},{"trials":632,"activeCount":51},[],{"trials":634,"activeCount":51},[],{"trials":636,"activeCount":51},[637],{"nctId":638,"briefTitle":639,"status":86,"phases":640,"primaryCompletion":641,"completion":641,"start":642,"enrollment":423,"conditions":643,"interventions":646},"NCT00163748","Efficacy and Treatment Related Toxicity Study of a New Regimen for Lymphoma",[42],"2003-11","2001-02",[644,645],"Non-Hodgkin's Lymphoma","Hodgkin's Disease",[629],{"trials":648,"activeCount":51},[],{"trials":650,"activeCount":51},[],{"trials":652,"activeCount":51},[],{"intervention":654,"totalTrials":8,"cells":655},"Azacitidine",{"EARLY_PHASE1":656,"PHASE1":658,"PHASE2":660,"PHASE3":672,"PHASE4":674,"NA":676},{"trials":657,"activeCount":51},[],{"trials":659,"activeCount":51},[],{"trials":661,"activeCount":51},[662],{"nctId":663,"briefTitle":664,"status":141,"phases":665,"primaryCompletion":666,"completion":666,"start":667,"enrollment":668,"conditions":669,"interventions":671},"NCT00412919","Study of Azacitidine to Treat Relapsed or Refractory Multiple Myeloma",[42],"2008-11","2006-12",7,[670],"Multiple Myeloma",[654],{"trials":673,"activeCount":51},[],{"trials":675,"activeCount":51},[],{"trials":677,"activeCount":51},[],{"intervention":679,"totalTrials":8,"cells":680},"Liposomal amphotericin B",{"EARLY_PHASE1":681,"PHASE1":683,"PHASE2":685,"PHASE3":696,"PHASE4":698,"NA":700},{"trials":682,"activeCount":51},[],{"trials":684,"activeCount":51},[],{"trials":686,"activeCount":51},[687],{"nctId":688,"briefTitle":689,"status":241,"phases":690,"completion":269,"start":691,"enrollment":692,"conditions":693,"interventions":695},"NCT00451711","Intermittent Liposomal Amphotericin B Primary Prophylaxis",[42],"2007-05",60,[694],"Acute Myeloid Leukemia",[679],{"trials":697,"activeCount":51},[],{"trials":699,"activeCount":51},[],{"trials":701,"activeCount":51},[],{"intervention":703,"totalTrials":8,"cells":704},"Favipiravir",{"EARLY_PHASE1":705,"PHASE1":707,"PHASE2":709,"PHASE3":722,"PHASE4":724,"NA":726},{"trials":706,"activeCount":51},[],{"trials":708,"activeCount":51},[],{"trials":710,"activeCount":51},[711],{"nctId":712,"briefTitle":713,"status":241,"phases":714,"primaryCompletion":715,"completion":716,"start":717,"enrollment":718,"conditions":719,"interventions":721},"NCT04445467","An Adaptive Clinical Trial of Antivirals for COVID-19 Infection",[42],"2021-11","2021-12","2020-07-30",190,[720],"COVID",[703],{"trials":723,"activeCount":51},[],{"trials":725,"activeCount":51},[],{"trials":727,"activeCount":51},[],{"intervention":729,"totalTrials":8,"cells":730},"4% Albumin \u002F 0.9% Sodium Chloride",{"EARLY_PHASE1":731,"PHASE1":733,"PHASE2":735,"PHASE3":751,"PHASE4":753,"NA":755},{"trials":732,"activeCount":51},[],{"trials":734,"activeCount":51},[],{"trials":736,"activeCount":51},[737],{"nctId":738,"briefTitle":739,"status":86,"phases":740,"primaryCompletion":741,"completion":741,"start":742,"enrollment":743,"conditions":744,"interventions":750},"NCT00228657","Formation and Severity of Pressure Ulcers Associated With 4% Albumin vs. 0.9% Sodium Chloride",[41,42],"2003-08","2002-07",1100,[745,746,747,748,749],"Pressure Ulcer, Area","Pressure Ulcer, Grade","Albumin Level","Risk Score","Length of ICU Stay",[729],{"trials":752,"activeCount":51},[],{"trials":754,"activeCount":51},[],{"trials":756,"activeCount":51},[],{"intervention":758,"totalTrials":8,"cells":759},"gemcitabine, vinorelbine, ifosfamide, filgastrim",{"EARLY_PHASE1":760,"PHASE1":762,"PHASE2":764,"PHASE3":775,"PHASE4":777,"NA":779},{"trials":761,"activeCount":51},[],{"trials":763,"activeCount":51},[],{"trials":765,"activeCount":51},[766],{"nctId":767,"briefTitle":768,"status":86,"phases":769,"primaryCompletion":593,"completion":593,"start":770,"enrollment":771,"conditions":772,"interventions":773},"NCT00163761","Efficacy Study of Outpatient Therapy for Lymphoma",[42],"2002-12",90,[644,645],[758,774],"gemcitabine, vinorelbine, filgastrim",{"trials":776,"activeCount":51},[],{"trials":778,"activeCount":51},[],{"trials":780,"activeCount":51},[],{"intervention":774,"totalTrials":8,"cells":782},{"EARLY_PHASE1":783,"PHASE1":785,"PHASE2":787,"PHASE3":793,"PHASE4":795,"NA":797},{"trials":784,"activeCount":51},[],{"trials":786,"activeCount":51},[],{"trials":788,"activeCount":51},[789],{"nctId":767,"briefTitle":768,"status":86,"phases":790,"primaryCompletion":593,"completion":593,"start":770,"enrollment":771,"conditions":791,"interventions":792},[42],[644,645],[758,774],{"trials":794,"activeCount":51},[],{"trials":796,"activeCount":51},[],{"trials":798,"activeCount":51},[],{"intervention":800,"totalTrials":8,"cells":801},"gemcitabine",{"EARLY_PHASE1":802,"PHASE1":804,"PHASE2":806,"PHASE3":820,"PHASE4":822,"NA":824},{"trials":803,"activeCount":51},[],{"trials":805,"activeCount":51},[],{"trials":807,"activeCount":51},[808],{"nctId":809,"briefTitle":810,"status":86,"phases":811,"completion":594,"start":812,"enrollment":813,"conditions":814,"interventions":816},"NCT00280878","Rituximab in Combination With Outpatient Therapy for CD20+ Lymphoma",[42],"2006-01",12,[815],"Non-Hodgkin's Lymphoma (CD20+)",[800,817,818,819],"vinorelbine","ifosfamide","rituximab",{"trials":821,"activeCount":51},[],{"trials":823,"activeCount":51},[],{"trials":825,"activeCount":51},[],{"intervention":817,"totalTrials":8,"cells":827},{"EARLY_PHASE1":828,"PHASE1":830,"PHASE2":832,"PHASE3":838,"PHASE4":840,"NA":842},{"trials":829,"activeCount":51},[],{"trials":831,"activeCount":51},[],{"trials":833,"activeCount":51},[834],{"nctId":809,"briefTitle":810,"status":86,"phases":835,"completion":594,"start":812,"enrollment":813,"conditions":836,"interventions":837},[42],[815],[800,817,818,819],{"trials":839,"activeCount":51},[],{"trials":841,"activeCount":51},[],{"trials":843,"activeCount":51},[],{"intervention":818,"totalTrials":8,"cells":845},{"EARLY_PHASE1":846,"PHASE1":848,"PHASE2":850,"PHASE3":856,"PHASE4":858,"NA":860},{"trials":847,"activeCount":51},[],{"trials":849,"activeCount":51},[],{"trials":851,"activeCount":51},[852],{"nctId":809,"briefTitle":810,"status":86,"phases":853,"completion":594,"start":812,"enrollment":813,"conditions":854,"interventions":855},[42],[815],[800,817,818,819],{"trials":857,"activeCount":51},[],{"trials":859,"activeCount":51},[],{"trials":861,"activeCount":51},[],{"intervention":819,"totalTrials":8,"cells":863},{"EARLY_PHASE1":864,"PHASE1":866,"PHASE2":868,"PHASE3":874,"PHASE4":876,"NA":878},{"trials":865,"activeCount":51},[],{"trials":867,"activeCount":51},[],{"trials":869,"activeCount":51},[870],{"nctId":809,"briefTitle":810,"status":86,"phases":871,"completion":594,"start":812,"enrollment":813,"conditions":872,"interventions":873},[42],[815],[800,817,818,819],{"trials":875,"activeCount":51},[],{"trials":877,"activeCount":51},[],{"trials":879,"activeCount":51},[],{"intervention":881,"totalTrials":8,"cells":882},"Vorinostat",{"EARLY_PHASE1":883,"PHASE1":885,"PHASE2":887,"PHASE3":899,"PHASE4":901,"NA":903},{"trials":884,"activeCount":51},[],{"trials":886,"activeCount":51},[],{"trials":888,"activeCount":51},[889],{"nctId":890,"briefTitle":891,"status":241,"phases":892,"primaryCompletion":131,"completion":893,"start":894,"enrollment":895,"conditions":896,"interventions":898},"NCT01365065","Safety and Effect on HIV Transcription of Vorinostat in Patients Receiving Suppressive Combination Anti-retroviral Therapy",[42],"2018-01","2011-05",20,[897],"HIV Positive",[881],{"trials":900,"activeCount":51},[],{"trials":902,"activeCount":51},[],{"trials":904,"activeCount":51},[],{"intervention":906,"totalTrials":8,"cells":907},"3BNC117-Copper-64",{"EARLY_PHASE1":908,"PHASE1":910,"PHASE2":921,"PHASE3":923,"PHASE4":925,"NA":927},{"trials":909,"activeCount":51},[],{"trials":911,"activeCount":51},[912],{"nctId":913,"briefTitle":914,"status":86,"phases":915,"primaryCompletion":916,"completion":917,"start":918,"enrollment":495,"conditions":919,"interventions":920},"NCT03063788","Imaging the HIV Reservoir",[41],"2020-02-01","2020-04-01","2018-09-18",[195],[906],{"trials":922,"activeCount":51},[],{"trials":924,"activeCount":51},[],{"trials":926,"activeCount":51},[],{"trials":928,"activeCount":51},[],{"intervention":930,"totalTrials":8,"cells":931},"atorvastatin",{"EARLY_PHASE1":932,"PHASE1":934,"PHASE2":943,"PHASE3":945,"PHASE4":947,"NA":949},{"trials":933,"activeCount":51},[],{"trials":935,"activeCount":51},[936],{"nctId":937,"briefTitle":938,"status":241,"phases":939,"conditions":940,"interventions":942},"NCT00164086","Atorvastatin in Myeloma",[41],[941],"Myeloma",[930],{"trials":944,"activeCount":51},[],{"trials":946,"activeCount":51},[],{"trials":948,"activeCount":51},[],{"trials":950,"activeCount":51},[],{"intervention":952,"totalTrials":8,"cells":953},"RAD001",{"EARLY_PHASE1":954,"PHASE1":956,"PHASE2":967,"PHASE3":969,"PHASE4":971,"NA":973},{"trials":955,"activeCount":51},[],{"trials":957,"activeCount":51},[958],{"nctId":959,"briefTitle":960,"status":241,"phases":961,"primaryCompletion":962,"completion":963,"start":964,"enrollment":423,"conditions":965,"interventions":966},"NCT00636922","Everolimus (RAD001) in Elderly Patients With Acute Myeloid Leukemia",[41],"2013-07","2014-01","2010-02",[694],[952],{"trials":968,"activeCount":51},[],{"trials":970,"activeCount":51},[],{"trials":972,"activeCount":51},[],{"trials":974,"activeCount":51},[],{"intervention":976,"totalTrials":8,"cells":977},"Norfloxacin",{"EARLY_PHASE1":978,"PHASE1":980,"PHASE2":982,"PHASE3":984,"PHASE4":986,"NA":988},{"trials":979,"activeCount":51},[],{"trials":981,"activeCount":51},[],{"trials":983,"activeCount":51},[],{"trials":985,"activeCount":51},[],{"trials":987,"activeCount":51},[],{"trials":989,"activeCount":51},[990],{"nctId":991,"briefTitle":992,"status":241,"phases":993,"conditions":994,"interventions":996},"NCT00163982","Vasoactive Peptides in Portal Pressure",[45],[995],"Portal Hypertension",[976],{"intervention":998,"totalTrials":8,"cells":999},"ephedrine hydrochloride",{"EARLY_PHASE1":1000,"PHASE1":1002,"PHASE2":1004,"PHASE3":1006,"PHASE4":1008,"NA":1010},{"trials":1001,"activeCount":51},[],{"trials":1003,"activeCount":51},[],{"trials":1005,"activeCount":51},[],{"trials":1007,"activeCount":51},[],{"trials":1009,"activeCount":51},[],{"trials":1011,"activeCount":51},[1012],{"nctId":1013,"briefTitle":1014,"status":86,"phases":1015,"primaryCompletion":1016,"start":1017,"enrollment":1018,"conditions":1019,"interventions":1020},"NCT01015794","Activation of Cervical and Upper Thoracic Brown Adipose Tissue in Humans Via Beta-adrenergic Stimulation",[45],"2012-12","2009-12",25,[22],[998,998],{"intervention":1022,"totalTrials":8,"cells":1023},"Administration of wine fined with potential food allergens",{"EARLY_PHASE1":1024,"PHASE1":1026,"PHASE2":1028,"PHASE3":1030,"PHASE4":1032,"NA":1034},{"trials":1025,"activeCount":51},[],{"trials":1027,"activeCount":51},[],{"trials":1029,"activeCount":51},[],{"trials":1031,"activeCount":51},[],{"trials":1033,"activeCount":51},[],{"trials":1035,"activeCount":51},[1036],{"nctId":1037,"briefTitle":1038,"status":86,"phases":1039,"primaryCompletion":1040,"completion":1040,"start":1041,"enrollment":1042,"conditions":1043,"interventions":1046},"NCT00163735","Potential Allergens in Wine: Double-blind Placebo-controlled Trial",[45],"2006-05","2002-08",48,[1044,1045],"Food Allergy","Anaphylaxis",[1022],{"intervention":1048,"totalTrials":8,"cells":1049},"urotensin II",{"EARLY_PHASE1":1050,"PHASE1":1052,"PHASE2":1054,"PHASE3":1056,"PHASE4":1058,"NA":1060},{"trials":1051,"activeCount":51},[],{"trials":1053,"activeCount":51},[],{"trials":1055,"activeCount":51},[],{"trials":1057,"activeCount":51},[],{"trials":1059,"activeCount":51},[],{"trials":1061,"activeCount":51},[1062],{"nctId":1063,"briefTitle":1064,"status":241,"phases":1065,"enrollment":423,"conditions":1066,"interventions":1069},"NCT00163995","Urotensin II and Vascular Tone in Cirrhosis",[],[1067,1068],"Liver Diseases","Cirrhosis",[1048],{"intervention":1071,"totalTrials":8,"cells":1072},"Posaconazole",{"EARLY_PHASE1":1073,"PHASE1":1075,"PHASE2":1077,"PHASE3":1079,"PHASE4":1081,"NA":1083},{"trials":1074,"activeCount":51},[],{"trials":1076,"activeCount":51},[],{"trials":1078,"activeCount":51},[],{"trials":1080,"activeCount":51},[],{"trials":1082,"activeCount":51},[],{"trials":1084,"activeCount":51},[1085],{"nctId":1086,"briefTitle":1087,"status":241,"phases":1088,"primaryCompletion":1089,"completion":1089,"start":1090,"enrollment":895,"conditions":1091,"interventions":1092},"NCT03421366","Modified Release Posaconazole in Patients With Cystic Fibrosis",[],"2021-02-05","2018-03-01",[17],[1071],{"intervention":1094,"totalTrials":8,"cells":1095},"Niacin\u002FLaropiprant combination",{"EARLY_PHASE1":1096,"PHASE1":1098,"PHASE2":1100,"PHASE3":1102,"PHASE4":1104,"NA":1106},{"trials":1097,"activeCount":51},[],{"trials":1099,"activeCount":51},[],{"trials":1101,"activeCount":51},[],{"trials":1103,"activeCount":51},[],{"trials":1105,"activeCount":51},[],{"trials":1107,"activeCount":51},[1108],{"nctId":1109,"briefTitle":1110,"status":141,"phases":1111,"primaryCompletion":1112,"completion":1112,"start":1113,"enrollment":668,"conditions":1114,"interventions":1116},"NCT01391377","Effects of Niacin on Good Cholesterol in People With Peripheral Arterial Disease",[45],"2014-12","2011-07",[1115],"Peripheral Arterial Disease",[1094,1117],"Sugar pill",{"intervention":1117,"totalTrials":8,"cells":1119},{"EARLY_PHASE1":1120,"PHASE1":1122,"PHASE2":1124,"PHASE3":1126,"PHASE4":1128,"NA":1130},{"trials":1121,"activeCount":51},[],{"trials":1123,"activeCount":51},[],{"trials":1125,"activeCount":51},[],{"trials":1127,"activeCount":51},[],{"trials":1129,"activeCount":51},[],{"trials":1131,"activeCount":51},[1132],{"nctId":1109,"briefTitle":1110,"status":141,"phases":1133,"primaryCompletion":1112,"completion":1112,"start":1113,"enrollment":668,"conditions":1134,"interventions":1135},[45],[1115],[1094,1117],{"intervention":1137,"totalTrials":8,"cells":1138},"TMS",{"EARLY_PHASE1":1139,"PHASE1":1141,"PHASE2":1143,"PHASE3":1145,"PHASE4":1147,"NA":1149},{"trials":1140,"activeCount":51},[],{"trials":1142,"activeCount":51},[],{"trials":1144,"activeCount":51},[],{"trials":1146,"activeCount":51},[],{"trials":1148,"activeCount":51},[],{"trials":1150,"activeCount":51},[1151],{"nctId":1152,"briefTitle":1153,"status":86,"phases":1154,"primaryCompletion":1155,"completion":1155,"start":1156,"enrollment":11,"conditions":1157,"interventions":1158},"NCT00402220","A Double-blind Sham Controlled Trial of rTMS in Treatment Resistant Major Depression",[45],"2011-01","2007-03",[93],[1137],{"intervention":1160,"totalTrials":8,"cells":1161},"Anti-reflux pharmacotherapy",{"EARLY_PHASE1":1162,"PHASE1":1164,"PHASE2":1166,"PHASE3":1168,"PHASE4":1170,"NA":1172},{"trials":1163,"activeCount":51},[],{"trials":1165,"activeCount":51},[],{"trials":1167,"activeCount":51},[],{"trials":1169,"activeCount":51},[],{"trials":1171,"activeCount":51},[],{"trials":1173,"activeCount":51},[1174],{"nctId":1175,"briefTitle":1176,"status":241,"phases":1177,"primaryCompletion":1178,"start":642,"enrollment":1179,"conditions":1180,"interventions":1181},"NCT00164021","The Prevalence and Significance of Gastro-oesophageal Reflux in Cystic Fibrosis Before and After Lung Transplantation",[],"2016-12",180,[17],[1160],{"intervention":1183,"totalTrials":8,"cells":1184},"Ephedrine, pioglitazone",{"EARLY_PHASE1":1185,"PHASE1":1187,"PHASE2":1189,"PHASE3":1191,"PHASE4":1193,"NA":1195},{"trials":1186,"activeCount":51},[],{"trials":1188,"activeCount":51},[],{"trials":1190,"activeCount":51},[],{"trials":1192,"activeCount":51},[],{"trials":1194,"activeCount":51},[],{"trials":1196,"activeCount":51},[1197],{"nctId":1198,"briefTitle":1199,"status":241,"phases":1200,"primaryCompletion":1112,"start":1201,"enrollment":133,"conditions":1202,"interventions":1203},"NCT02236962","Enhancement of Brown Adipose Tissue Function Via Chronic Pharmacological Treatment",[45],"2012-04",[19,22,27],[1183],{"intervention":1205,"totalTrials":8,"cells":1206},"rHDL",{"EARLY_PHASE1":1207,"PHASE1":1209,"PHASE2":1211,"PHASE3":1213,"PHASE4":1215,"NA":1217},{"trials":1208,"activeCount":51},[],{"trials":1210,"activeCount":51},[],{"trials":1212,"activeCount":51},[],{"trials":1214,"activeCount":51},[],{"trials":1216,"activeCount":51},[],{"trials":1218,"activeCount":51},[1219],{"nctId":1220,"briefTitle":1221,"status":86,"phases":1222,"primaryCompletion":1223,"completion":1223,"start":1224,"enrollment":1225,"conditions":1226,"interventions":1229},"NCT00395148","Improving Metabolism With HDL Cholesterol",[45],"2008-03","2006-03",13,[1227,1228],"Heart Disease","Diabetes",[1205],{"intervention":1231,"totalTrials":8,"cells":1232},"fungalAi platform technology",{"EARLY_PHASE1":1233,"PHASE1":1235,"PHASE2":1237,"PHASE3":1239,"PHASE4":1241,"NA":1243},{"trials":1234,"activeCount":51},[],{"trials":1236,"activeCount":51},[],{"trials":1238,"activeCount":51},[],{"trials":1240,"activeCount":51},[],{"trials":1242,"activeCount":51},[],{"trials":1244,"activeCount":51},[1245],{"nctId":1246,"briefTitle":1247,"status":241,"phases":1248,"primaryCompletion":1249,"completion":1249,"start":1250,"enrollment":1251,"conditions":1252,"interventions":1254},"NCT03793231","fungalAi for Fungal Surveillance & Antifungal Stewardship",[],"2020-12-30","2019-01-01",1000,[1253],"Fungal Infections",[1231]]